Episode Player

Send us Fan Mail

A product can be ready for the world and still be held back by one thing: how regulators choose to classify it. We sit down again with Dr Peter Molloy, Executive Chairman of Firebrick Pharma, to unpack the company’s shift from R&D to commercial execution and why a single regulatory milestone in Indonesia changes the scale of the Nasodine opportunity.

Peter walks us through the origin story that starts with Betadine and leads to Nasodine, a povidone-iodine nasal spray designed to target the viral cause of the common cold using a topical antiseptic approach. We dig into why povidone-iodine remains compelling after decades of use, how low concentrations can still be potent, and why the “no resistance” profile matters when consumers are surrounded by symptom-only OTC options. Just as importantly, we talk about the practical reality for ASX health companies: Australia’s TGA can treat products like Nasodine as a drug, while markets such as Singapore may treat it as an antiseptic, dramatically changing time, cost, and pathway to market.

From there, the conversation turns to growth: Indonesia’s approval and its 60 to 65 million middle and upper-middle class consumers, the Philippines as the next potential major approval, and plans to broaden the Nasodine product range. We also cover the business model behind the strategy, including licensing partnerships that reduce manufacturing and marketing burden, recent capital raising, cash burn, and what “runway” looks like in a tough funding environment. If you’re following Firebrick Pharma, Nasodine, or healthcare commercialisation in Southeast Asia, this is the roadmap and the reality check.

Subscribe for more ASX Briefs, share this with a mate who follows biotech, and leave a review with your biggest question about Nasodine’s path to global markets.